Literature DB >> 27161091

Routine delayed voiding cystourethography after initial successful endoscopic treatment with Dextranomer/Hialuronic Acid Copolimer (Dx/HA) of vesicoureteral reflux (VUR). Is it necessary?

L García-Aparicio1, E Blázquez-Gómez2, A Vila Santandreu3, J A Camacho Diaz3, J Vila-Cots3, M Ramos Cebrian3, I de Haro4, O Martin5, X Tarrado4.   

Abstract

INTRODUCTION: Some guidelines recommend an early voiding cystourethrography (VCUG) after endoscopic treatment of vesicoureteral reflux (VUR), but there's no consensus if it's necessary a long-term follow-up in these patients. The aim of our study is analyze if it's necessary a delayed VCUG after initial successful treatment with Dx/HA. MATERIAL AND
METHOD: We have reviewed all medical charts of patients that underwent Dx/HA treatment from 2006 to 2010. We have selected patients with initial successful treatment and more than 3 years of radiological and clinical follow-up. We have analyzed late clinical and radiological outcomes.
RESULTS: One hundred and sixty children with 228 refluxing ureters underwent Dx/HA endoscopic treatment with a mean follow-up of 52.13 months. Early VCUG was performed in 215 ureters with an initial successful rate of 84.1%. The group of study was 94/215 ureters with more than 3 years of follow-up with a delayed VCUG. VUR was still resolved in 79,8% of the ureters. Clinical success rate was 91.7%. The incidence of febrile urinary tract infection in those patients with cured VUR and those with a relapsed VUR was 8 and 15%, respectively; but there were no significant differences. We have not found any variable related with relapsed VUR except those ureters that initially received 2 injections (P<.05).
CONCLUSION: If our objective in the treatment of VUR is to reduce the incidence of febrile urinary tract infection it is not necessary to perform a delayed VCUG even though the long-term radiological outcomes is worse than clinical outcome.
Copyright © 2016 AEU. Publicado por Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Children; Cistografía; Cystography; Endoscopia; Endoscopy; Infancia; Reflujo vesicoureteral; Vesicoureteral reflux

Mesh:

Substances:

Year:  2016        PMID: 27161091     DOI: 10.1016/j.acuro.2016.02.007

Source DB:  PubMed          Journal:  Actas Urol Esp        ISSN: 0210-4806            Impact factor:   0.994


  2 in total

1.  Randomized clinical trial between polyacrylate-polyalcohol copolymer (PPC) and dextranomer-hyaluronic acid copolymer (Dx/HA) as bulking agents for endoscopic treatment of primary vesicoureteral reflux (VUR).

Authors:  L García-Aparicio; E Blázquez-Gómez; O Martin; S Pérez-Bertólez; J Arboleda; A Soria; X Tarrado
Journal:  World J Urol       Date:  2018-05-03       Impact factor: 4.226

2.  Long-Term Clinical Outcomes and Parental Satisfaction After Dextranomer/Hyaluronic Acid (Dx/HA) Injection for Primary Vesicoureteral Reflux.

Authors:  Michelle Lightfoot; Aylin N Bilgutay; Noah Tollin; Scott Eisenberg; Jake Weiser; Leah Bryan; Edwin Smith; James Elmore; Hal Scherz; Andrew J Kirsch
Journal:  Front Pediatr       Date:  2019-09-27       Impact factor: 3.418

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.